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Abstract
Background: Calcium and vitamin D play an essential role in bone metabolism but deficiency and/or
inadequate intake are common.
Objectives: To describe a practical approach based on the literature regarding clinically important aspects of
calcium and vitamin D supplementation.
Methods: A systematic evaluation of relevant literature in Medline was conducted. We included physiological
studies, publications on relevant guidelines, meta-analysis, randomized clinical trials, and cohort studies.
Results: An adequate calcium intake and vitamin D supplementation is recommended in most guidelines xon
fracture prevention. Daily supplementation with 800 IU is advocated in most guidelines, appears to be safe,
and with this approach it is generally not necessary to determine vitamin D levels. There are no data on
additional effects of loading doses of vitamin D on fracture or fall prevention. Calcium supplementation
should be tailored to the patient’s need: usually 500 mg per day is required. The intestinal absorption of
calcium citrate is approximately 24% better than that of calcium carbonate independent of intake with meals.
Data on difference between calcium absorption with calcium carbonate compared to calcium citrate with
simultaneous use of proton pump inhibitors are lacking. Concern has arisen about a possible link between
calcium supplementation and an increased risk of myocardial infarction. Probably only well-designed
prospective randomized controlled trials will be able to allow definite conclusions on this subject.
Conclusion: Daily supplementation with 800 IU vitamin D is a practical and safe strategy without the need
for prior determination of vitamin D levels. Calcium supplementation should be tailored to the patient’s need
based on total daily dietary calcium intake. In most patients 500 mg per day is required to achieve a total
intake of 1,200 mg, or in some 1,000 mg per day. More calcium is absorbed from calcium citrate compared to
calcium carbonate.
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T
he essential role of calcium for bone metabolism
has been known since the animal studies (in 1928)
and calcium balance studies (in 1946) performed
by Albright (1). Rickets was first described more than
300 years ago (Glisson, 15991677), but the essential
role of vitamin D with regards to bone metabolism only
became clear following animal experiments with liver oil
supplements by McCollum (2).
Vitamin D supplements reduce the risk of falls and
fractures in vitamin D-deficient subjects. Vitamin D
deficiency is worldwide considered endemic and there-
fore vitamin D supplementation is recommended in most
guidelines on fracture prevention.
Inadequate intake of calcium via the diet is also
common, even more so in patients with a recent fracture,
and adequate calcium intake is recommended in the
guidelines. The absorption of calcium from the intestines
occurs by means of an active, vitamin D-dependent
process and to a lesser extent by passive diffusion and is
determined  among other factors  by the solubility of
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intestinal system. Observational research indicates that
excessive calcium intake could increase the risk of cardi-
ovascular events.
I nd a i l yp r a c t i c e ,t h ec a r eo fa d e q u a t ec a l c i u m
homeostasis will depend on the need of vitamin D
and calcium. There are, however, few all-encompassing
studies available about the relationship between the
dosage of vitamin D supplementation and changes in
serum 25(OH)D to answer questions about the need
amongst the elderly, the target values for serum levels,
and the quantity and frequency of vitamin D supple-
ments. For calcium intake, the question that arises is
what the minimum and maximum calcium dosages
should be for recommendation.
This overview aims to provide an answer to these
questions, based on a review of relevant literature.
Calcium and vitamin D recommendations in
Guidelines on Osteoporosis and Fracture Prevention
The 2011 Dutch Guideline on Osteoporosis and Frac-
ture Prevention (CBO Guideline) advises in the case of
patients taking medication to prevent fractures to aim for
a total calcium intake (diet and supplements) of 1,000
1,200 mg calcium per day and an intake of vitamin D
supplements of 800 IU per day (3).
The United Kingdom NICE 2012 guidelines on
fractures and osteoporosis, that are mainly focused on
fracture risk and other related NICE guidelines, have
no special focus on calcium and vitamin D (http://www.
nice.org.uk/nicemedia/live/13857/60399/60399.pdf) (last
assessed on April 24, 2013). A new guideline on vitamin
D will be available in 2014. Canadian guidelines (4)
advise intake of 1,200 mg calcium daily in women
50 years and older and men 70 years and older. The
vitamin D intake in elderly persons should be 1,000
1,200 IU daily. The Australian guideline (http://www.
osteoporosis.org.au/images/stories/updatedthinkgp.pdf)
(last assessed on April 24th 2013) advises for women over
50 years of age a calcium intake of 1,300 mg per day
and a vitamin D intake of 800 IE. In the international
literature, there is no consensus on the daily vitamin D
supplementary intake (5).
In a recent statement, the US Preventive Services
Task Force (USPSTF) recommends against daily supple-
mentation with 400 IU or less of vitamin D and 1,000 mg
or less of calcium for the primary prevention of frac-
tures in non-institutionalized post-menopausal women
(6). The USPSTF concludes that the current evidence
is insufficient to assess the balance of the benefits and
harms of daily supplementation with greater than 400
IU of vitamin D and greater than 1,000 mg of calcium
for the primary prevention of fractures in the same
population (6).
Meta-analyses reveal that calcium supplementation
reduces the risk of non-vertebral fractures, with the effect
being amplified in combination with vitamin D (7, 8),
particularly for hip fracture reduction (9). Supplementa-
tion of 4001,200 IU of vitamin D per day for the elderly
( 65 years), in combination with calcium, results in a
relative reduction of the occurrence of non-vertebral
fractures of 1020% (10, 11).
An association between vitamin D deficiency, falls,
and fracture rates in older women and men has been
demonstrated in several studies (1214).
In a 1-year randomized, population-based, controlled
t r i a l1 , 0 0 0I Uo fd a i l yo r a le r g o c a l c i f e r o lt r e a t m e n t
reduced the risk of falling over a year by about one-
third in women with a serum 25 hydroxyvitamin D
(25OHD) B60 nmol/L and a history of falls in the
previous year (15).
In all randomized clinical trials on the effect of
drugs with fracture prevention as primary endpoint,
both the intervention group and the placebo group were
supplemented with vitamin D and calcium (Table 1).
However, there were large differences in the amount of
calcium and vitamin D supplements in the various
fracture studies.
Most of these studies were performed with standard
dosages of 2501,200 IU/ day for vitamin D and 500
1,000 mg per day for calcium or dosages of calcium and
vitamin D supplements adjusted for dietary intake and
serum values of 25(OH)D. In some studies, vitamin D
supplements were given before the start of the study, in
daily doses during several weeks to months, or in bolus
up to 125,000 IU.
Mechanism and functional aspects of intestinal
absorption of the calcium salts
The intestinal calcium absorption has been studied
extensively in balance studies in patients with chronic
renal insufficiency, revealing that a dietary intake of
1,000 mg calcium results in approximately 400 mg being
absorbed in the digestive tract, whilst 200 mg of calcium
is added to the intestinal lumen via excretion. The total
amount of calcium that passes the digestive tract is
therefore 1,200 mg, of which 800 mg is excreted via
the feces. This means that the average fractional calcium
absorption is 400/1,2000.33 (16, 17). The serum
calcium level and the 24-h calcium excretion can be
measured accurately in clinical practice, but the actual
quantity of calcium that is absorbed by the bones is
much more difficult to measure. This requires the use of
‘bio-markers’, absorption of calcium isotopes, or  after
extended treatment  bone densitometry. The absorption
of calcium occurs primarily in the small intestine via an
active trans-cellular process on the one hand, regulated
by active vitamin D (1.25 (OH)2D3), and via para-cellular
diffusion on the other hand (18, 19), the latter being
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process that can become saturated and is particularly
important in the event of limited calcium intake. This
results in an upregulation of the production of active
vitamin D. As the fractional calcium absorption is
significantly determined by active vitamin D, vitamin
D deficiency will also result in decreased calcium
absorption. Heaney et al. demonstrated that the calcium
absorption increases up to a serum 25(OH)D level of
80 nmol/L and reaches a plateau at  80 nmol/L (Fig. 1)
(20). Assuming the fact that approximately 35% of the
available calcium is absorbed in the gastrointestinal
system, the question is how significant the contributions
of the active and passive transport systems are and in
which parts of the gastrointestinal system this absorption
occurs.
The course of calcium absorption and, in particular,
the contribution of active and passive absorption of
calcium over the course of the jejunum, ileum, and colon
is presented in Fig. 2 (19, 21).
The solubility of the type of calcium salts is impor-
tant for this absorption process, because calcium can only
be absorbed in dissolved form (24, 25). However, the
solubility of calcium is primarily dependent on pH, so
that the pH of the digestive tract is an important factor in
this absorption process. In addition, factors such as pCO2
and the quantity of bicarbonate and phosphate play
an additional role in the calcium absorption process.
It is known that the pH changes over the course of the
digestive tract: very low in the stomach (pH 12),
approximately pH 6 in the duodenum, gradually increas-
ing in the small intestine from 6 or 6.5 in the proximal
jejunum to 7.4 in the middle of the small intestine and to
7.5 in the ileum. The pH then decreases to 6.4 in the
cecum and in the course of the colon gradually increases
again to 6.7 and finally to 7 in the rectum (Fig. 2)
(22, 26). The average pH is 7.3 in the small intestine and
6.6 in the colon (23).
In this context, it is important to realize that calcium is
not absorbed in the stomach, but in the small and large
intestine. The total amount of calcium that is absorbed
Table 1. Calcium and vitamin D supplementation in medicinal fracture intervention studies
Study Medicine Calcium, mg/d Vitamin D, IE/d
Black 1996 Alendronate 500 when required 250
Cummings 1996 Alendronate 500 when required 250
Harris 1999 Risedronate 1,000 500 when required
a
Reginster 2000 Risedronate 1,000 500 when required
a
McClung 2001 Risedronate 1,000 500 when required
a
Chestnut 2004 Ibandronate 500 400
Black 2007 Zoledronate 1,0001,500 4001,200
Lyles 2007 Zoledronaat hip 1,0001,500 25(OH)DB37.5 nmol/L or not measured:
Loading dose: 50120,000
Thereafter 8001,200
Ettinger Raloxifen 500 400600
Neer 2001 Teriparatide 1,000 4001,200
Greenspan 2007 PTH 700 400
Meunier 2004 SR*SOTI 01,000
b 400800
Reginster 2005 SR*TROPOS 01,000
b 400800
Cummings Denosumab 1,000 25(OH)D nmol/L:
3050: 800
 50: 400
aIf the vitamin D level was lower than 40 nmol/L.
bTo achieve a total intake of 1,000 mg per day.
SR*, strontium ranelate.
Fig. 1. Relationship between serum 25(OH)D level and
fractional calcium absorption (20).
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the passage time in the various segments of the small
and large intestine, and the amount of soluble calcium
available for absorption, which is primarily determined
by the pH in each segment of the gastrointestinal tract. In
the duodenum, and to a lesser extent the jejunum, there is
active calcium transport in addition to passive transport;
in the ileum there is primarily passive transport. The
largest quantity, namely 65% of the absorbed calcium,
is absorbed via passive transport in the ileum, because of
the length of this segment compared to the other parts
of the digestive tract (19, 21).
Calcium supplementation usually happens as a calcium
salt in the form of calcium carbonate or calcium citrate.
There are several calcium compounds available. When a
compound containing calcium carbonate is taken, this is
dissolved in the acidic environment of the stomach. When
a compound which contains calcium carbonate and citric
acid is taken then this will form calcium citrate when
dissolved in a glass of water. These various calcium
compounds are also available in various combination
preparations with low  400/440 IU  and higher  800/
880 IU  dosages of vitamin D.
The solubility of these salts has been tested in water,
showing that calcium citrate dissolved more completely
than calcium carbonate. However, dissolving calcium
citrate results in a pH of 5.6 and calcium carbonate in a
pH of 8.5, neither of which is an accurate reflection of
solubility in the digestive system. After all, the pH varies
per section of the digestive system and therefore the solu-
bility of the calcium salt will also vary per section (2729).
When the calcium salts are ingested and enter the
acidic environment of the stomach, dissolved calcium
ions become available (30).
CaCO3 (insoluble) 2 HCl 0 Ca
2þþ2Cl
 þH2OþCO2
Calcium carbonate Hydrochloric
acid
0 Soluble calcium ion
Carbon dioxide
Ca3ðC6H5O7Þ2:4H2O 6 HCl 0
2C6H5O
3 
7 þ6H
þþ3Ca
2þ
þ 6Cl
 þ4H2O
Calcium citrate Hydrochloric
acid
0 Citric acid
Soluble calcium ion
An increasing pH in the duodenum and jejunum
(due to bicarbonate production) will result in decreased
solubility of calcium because calcium salts are formed
once more:
CaCl2 þ 2NAHCO3 ! CaCO3 þ 2NaCl þ CO2 þ H2O
In vitro study of the pH-dependent solubility of cal-
cium carbonate compared to calcium citrate  taking
into consideration the CO2 tension that affects the
solubility in the digestive tract  shows that the solu-
bility of carbonate is higher at a pHB6.5 and the
solubility of the citrate form is higher at pH 6.5
(Fig. 3). At a pH of 7.5, the solubility of citrate is around
two times higher than that of carbonate. However, the
solubility of both calcium salts decreases with increasing
pH (2729).
If we translate this to the practical setting, there
are two clinical questions that need to be asked: Is the
calcium absorption with use of a calcium-containing
supplement the same for calcium carbonate and calcium
citrate? and Does the absorption of calcium carbonate
and calcium citrate differ in the event of a (relative) high
stomach pH, as is the case with the use of antacids or
hypochlorhydria or achlorhydria?
Fig. 2. Calcium absorption, solubility of calcium, contribution of active and passive absorption of calcium and pH in the
various segments of the small and large intestine (19, 22, 23).
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does have an effect on the solubility of the various
calcium salts, but because absorption occurs primarily
in the small and large intestine  particularly the ileum 
at a pH of around 7.5 (Fig. 2: 965% of the total calcium
absorption) it could well be that the pH of the stomach
is far less relevant and that the solubility of the calcium
salt in the pH range of 6.5 to 7.5 is of particular
importance. Of course, the fact that the in vitro models
do not correct for other factors, such as buffering by
amino acids, bile, and food components, should be taken
into consideration (2729).
The difference in calcium absorption with supplemen-
tation of calcium carbonate compared to calcium citrate
has been studied extensively. A meta-analysis was pub-
lished by Sakhaee et al. in 1999, which concluded that
calcium absorption was (statistically significant) 24%
higher in cases of supplementation with calcium citrate
compared with calcium carbonate, both when taken on
an empty stomach and when ingested during a meal
(Table 2, upper portion) (31). A number of studies have
beenpublishedsince1999aboutthissubject,usingvarious
techniques to determine calcium absorption, usually in
healthy study subjects or post-menopausal women and
applying various calcium dosages. The data of these
studies are presented in Table 2, lower portion.
The influence of achlorhydria and proton pump
inhibitors on calcium absorption
Literatureaboutthepresenceofachlorhydriaintheelderly
is limited. A systematic review by Hurwitz et al. (40)
Fig. 3. Concentration of dissolved elemental calcium
(Y-axis, log scale) depending on pH for calcium citrate (blue
line) and calcium carbonate (red line), corrected for CO2
tension in the digestive tract. Modiﬁed from Goss et al. (29).
Table 2. Clinical studies into the effect of intestinal calcium absorption with the use of calcium citrate versus calcium carbonate: the upper
portion lists the studies in the meta-analysis by Sakhaee et al. (31) and the lower portion lists the studies published thereafter
Author Year N Gender Population Method Calcium dosage (mg) Meal Effect citrate vs. carbonate (%)
Bo-Linn 1984 6 Normal Lavage 1,000  21.6
Nicar 1985 14 11 f, 3 m Normal Urine Ca excretion 1,000  70.5
Recker 1985 7 Normal Dual isotope 250  8.0
Reid 1986 10 Normal Urine Ca excretion 1,000  64.8
Smith 1987 10 f Normal Dual isotope 250  26.0
Harvey 1988 9 Normal Faecal recovery 100 or 200  28.0
Miller 1988 12 Children Dual isotope 250  36.9
Sheikh 1989 10 Normal Lavage 1,000  4.8
Harvey 1990 20 f Dual isotope 500  25.8
Harvey 1998 21 17 f, 4 m Urine Ca excretion 1,000  55.7
Heaney 1999 17 f Pre-men Serum radioactivity 300  10.8
Sakhaee 1999 Meta-analysis 24% pooled effect
Effect citrate vs. carbonate
Micheletti (32) 1996 14 Dual isotope 11,000 vs. 2500  Ca Ci
Heller (33) 1999 18 f Post-men Serum Ca, AUC Ca 500  Ci Ca
Heller (34) 2000 25 f Post-men 61 Serum Ca, AUC Ca, PTH,
urine Ca
500  4694
Heaney (35) 2001 24 f Post-men 58 AUC serum Ca, PTH, urine
Ca excretion
200  n.s.
Kenny (36) 2004 34 f PTH, BSAP, urine Ca excretion,
CTX, NTX
1,000 mg 12 week co  Ci Ca (CTX, NTX)
Hanzlik (37) 2005 14 f 1933 AUC Ca, PTH 1,200  Ci Ca
Thomas (38) 2008 25 f Post-men PTH, CTX 500 Ci and 1,000 Ca  Ci Ca
Karp (39) 12 f 2230 BSAP, serum Ca, PTH 1,000 
Ffemale, mmale, pre-menpre-menopausal, post-menpost-menopausal, n.s.not significant, AUCarea under the curve, BSAPbone-specific
alkaline phosphatase.
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consistent stomach pH of  3.5 at two consecutive
measurements and 67% had a consistently low pH.
A varying stomach pH (one time  3.5 and one time
B3.5) was found in 22% (40). The effect of achlorhydria
on the absorption of calcium with the use of various
supplements has not been studied in any detail.
The effect of proton pump inhibitors on calcium
absorption was studied in a review in 2008 (41). This
reveals that varying and small groups of patients were
studied, using different methods to evaluate calcium ab-
sorption and that a reliable answer cannot currently be
provided on the question whether the use of antacids
has a detrimental effect on calcium absorption (41). The
most recent article on this issue was a randomized trial
published in 2010 by the same author and revealed no
difference in intestinal calcium absorption between 20 mg
esomeprazole per day and placebo (42). There has been
no research to determine whether there is a difference in
calcium absorption between the various calcium salts
with use of proton pump inhibitors. Furthermore, the
conclusion inthe CBO Guideline is that evidencebased on
observational research suggesting that protonpump in-
hibitor (PPIs) are fracture-inducing medicines is very
weak, particularly as this association can also be linked
to the diseases for which the PPIs are prescribed (3, 43).
In conclusion, the in vitro data and models are complex
and do not entirely explain the calcium absorption
process in vivo. Clinical studies point consistently to
better absorption of calcium with use of citrate than with
carbonate. This difference appears to be explained by a
higher passive transport of calcium, because in the ileum
 where 65% of calcium is absorbed by means of passive
transport  calcium citrate dissolves better than calcium
carbonate at a pH ]7.5. Studies on the effect of proton
pump inhibitors on the absorption of calcium are not
unanimous in conclusion and have poor methodology,
any differences between calcium citrate and calcium
carbonate in this regard were not studied.
How much calcium and vitamin D should be
prescribed?
The average calcium intake in Great Britain for post-
menopausal women is 645705 mg calcium per day
(44). This figure is 720820 mg calcium per day in
Germany (45) and in France (46). The calcium intake
was also studied in the Netherlands: one-third of the
women in a study performed in Amsterdam consumed
less than 950 mg calcium per day (47); 18% of the women
of approximately the same age in a more rural area
(Ede, the Netherlands) consumed less than 800 mg per
day (48). In a population with an average age of 80 years,
living independently or in care homes, 25% consumed
less than 938 mg per day (49). This shows that there is
a large variation in the average calcium intake between
the different countries. In addition, there is a large
variation between individuals. It is particularly important
to know what the calcium intake is of those individuals
who are most in need of supplementation, for example,
the patients with a recent fracture. This was demonstrated
recently in a study in 502 patients over the age of 50 years
with a recent fracture: only 11% had a calcium intake
 1,000 mg per day in combination with serum 25(OH)D
levels  50 nmol/L (Fig. 4) (50). An excessively low serum
vitamin D level in combination with inadequate calcium
intake occurred in 43% (50).
As demonstrated in Fig. 5, this shortage applies to
both men and women, in all examined age categories
 50 years and with all types of fractures. It is note-
worthy that the inadequate calcium intake occurred in
equal measures with a normal BMD, osteopenia, and
osteoporosis. Therefore, inadequate calcium intake is an
endemic problem in patients presenting with a fracture
(50). Based on these data, one can conclude that one
should check the calcium intake and vitamin D level in all
fracture patients, even in those with a normal BMD.
Required calcium supplementation
Recently, the required calcium supplementation was
studied in patients with a recent fracture (50, 51). In
order to guarantee calcium intake of 1,000 per day, 12%
of patients required supplementation of 1,000 mg per day
and 57% required 500 mg. If one were to prescribe
500 mg calcium supplementation per day to all patients
for pragmatic reasons, this would only be inadequate
for achieving the required total intake of 1,000 mg per
day in 12% of the patients, whilst only a very small group
of patients achieves an unnecessary daily calcium intake
 1,500 mg. If one were to prescribe a standard 1,000 mg
calcium supplementation per day, nearly 90% would
exceed the limit of 1,500 mg per day. Except for a small
group requiring 1,000 mg per day because they consume
virtually no dairy products, 1,000 mg supplementation is
too high a level of substitution, particularly in the light
of indications about the potentially negative cardiovas-
cular effects of high-dose calcium supplementation.
With the use of corticosteroids, there are many factors
that play a role in increasing the risk of osteoporosis and
fractures. One of these is the reduced intestinal absorption
of calcium. A higher level of calcium intake is therefore
required. All studies in patients treated with corticoster-
oids gave supplementation of 1,0001,500 mg calcium per
day, which is more than the recommended supplementa-
tion dose for post-menopausal women and age-related
osteoporosis.
Required vitamin D supplementation
Dawson-Hughes et al. reported an estimated average
essential vitamin D intake of 8001,000 IU per day (20
25mgperday)inordertoachievea25(OH)D  75nmol/L
Robert Y. van der Velde et al.
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to ensure that virtually all elderly people achieve this level
of vitamin D (52). However, there are no arguments for
dosages higher than 800 IU per day (20 mg per day),
because there are not enough studies to support this.
Cranney et al. performed a meta-analysis in 2007 on the
relationship between serum 25(OH)D and the intake of
vitamin D form the diet. The conclusion of this study was
Fig. 4. Calcium intake and serum 25(OH)D in 50 patients with a recent fracture.
Fig. 5. Calcium intake and serum 25(OH)D in 50 patients with a recent fracture, according to gender, age, fracture location
and BMD.
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concentration, but it was not clear to which extent. The
large discrepancies between the various studies (differ-
ences in initial vitamin D levels, different populations,
different assays for vitamin D, etc.) made it impossible to
indicate how much vitamin D is required for whom (53).
Studies by Heaney (54) show that every 100 IU added
vitamin D causes the serum 25(OH)D level to increase by
2.5 nmol/L (range 1.752.75 nmol/L). Therefore, a dosage
of 800 IU will cause an increase in serum 25(OH)D of
approximately 20 nmol/L.
Based on the 25(OH)D levels in a study of 626 patients
with a recent fracture, one could theoretically  going out
from the starting point that every100 IU of addedvitamin
D causes a 2.5 nmol/L increase in the serum 25(OH)D
level  tailor the vitamin D supplementation in order to
achieve a level ]50 nmol/L in everyone (55) (Fig. 6).
In orderto achieve a level ]75 nmol/L in every patient,
one would theoretically have to give a dosage  800 IU
per day to at least 80% of the patients, evenup to 2,400 IU
per day (Fig. 6).
If one assumes a standard supplementation of 800 IU
vitamin D3, this will achieve a 25(OH)D ]50 nmol/L in
75% of the patients (Fig. 7).
A standard supplementation of 2,000 IU vitamin D3
would theoretically result in a 25(OH)D ]50 nmol/L in
100% of the patients and a 25(OH)D ]75 nmol/L in 90%
of the patients (Fig. 7).
In addition, there are as yet unidentified sub-groups
that require higherdosages of vitamin D3, such as patients
with a severe vitamin D deficiency with secondary
hyperparathyroidism. The first placebo-controlled study
on the effect of various daily dosages of vitamin D3
in healthy post-menopausal women with vitamin D
deficiency (25(OH)D B50 nmol/L) was published very
recently. The authors concluded that a dosage of 800 IU
per day resulted in an increase of the serum 25(OH)D
level to above 50nmol/L in 97.5% of the women, without
further increase after 12 months. These results show that
a daily dosage of 800 IU is sufficient for the majority of
post-menopausal women with vitamin D deficiency to
exceed the threshold of 50 nmol/L, which most guidelines
consider the desired threshold value of 25(OH)D (56).
Calcium intake and cardiovascular disease
Concern has arisen amongst doctors and patients follow-
ing the epidemiological study by Bolland et al. from 2008
(57). This study found a link between calcium supple-
mentation and an increased risk of myocardial infarction.
This study evaluated healthy elderly women who  in
addition to an average calcium intake of 860 mg per day 
received either a calcium supplement of 1,000 mg per day
or a placebo for five years in this randomized controlled
trial. A significant problem is therefore the general-
izability of the results of this study. Who would prescribe
such a high level of calcium to healthy women for such
a lengthy period?
Fig. 6. Required dose of vitamin D to achieve a 25(OH)D
level: ]50 (top panel) and ]75 nmol/L (bottom panel).
Fig. 7. 25(OH)D level achieved with use of a set dosage of
vitamin D supplementation (800 IU and 2,000 IU per day).
Robert Y. van der Velde et al.
8
(page number not for citation purpose)
Citation: Food & Nutrition Research 2014, 58: 21796 - http://dx.doi.org/10.3402/fnr.v58.21796There was a slightly increased risk of myocardial
infarction in the treated group.
The study by Lewis et al. (58) contradicts this. In this
study, 1,460 women aged 70 years or older were given a
calcium supplement of 1,200 mg or aplacebo. In addition,
these women consumed about 950 mg calcium via the
diet. In this study, the investigators found no evidence
that calcium supplementation causes an increased risk of
cardiovascular conditions during an average follow-up
of 4.5 years.
Several large observational studies performed more
than 10 years ago even show a favorable effect of calcium
supplementation such as the IOWA Health Study (59) and
the Nurses’ Health Study (60). The observed protective
effect of higher calcium intake in these studies is probably
due to the phenomenon of confounding by indication:
healthywomenwhoconsumemorecalcium,willingeneral
have a healthier lifestyle: more exercise, healthier diet,
and less smoking.
In a reanalysis of The Women’s Health Initiative
Study there was a slight increase in cardiovascular events
in the intervention group, most noticeable in myocardial
infarction (61).
In a recently published prospective (Swedish mammo-
gram) cohort study the use of calcium supplementa-
tion was not associated with cardiovascular mortality or
ischemic heart disease (62). In women who had a dietary
intake of  1,400 mg calcium per day, the use of calcium
supplements was associated with a higher all-cause
mortality rate (62).
In another recently published prospective observation
study an association of calcium supplementation with an
increased risk of cardiovascular mortality was found in
men but not in women (63).
To summarize, probably because of heterogeneity and
limitations in study design, the result of the different
studies are contradictory. Some show a cardio protective
effect of calcium supplementation. Other studies find an
increased risk of myocardial infarction, cardiac mor-
tality, and/or total mortality (but only with atotal calcium
intake greatly exceeding the usual recommendations).
Yet other studies find no significant relation between cal-
cium supplementation and cardiac events. Probably
only (well-designed and sufficiently powered) prospec-
tive randomized controlled trials with cardiac events as
a prespecified primary end point will be able to allow
definite conclusions on this subject. After an extensive
literaturesearch wehavecome totheconclusion that asup
to now no such studies have been published.
Calcium intake and drug interactions and adverse
effects
It is important to note that oral use of calcium salts
can reduce the absorption of bisphosphonates, tetracy-
clines (doxycycline, minocycline, and demeclocycline),
fluoroquinolones (ciprofloxacin, levofloxacin, norfloxa-
cin, ofloxacin, and moxifloxacin), levothyroxine, fiber-
rich food, and levodopa. For these medicines, it is
generally recommended to take these at least 2 h before
ingestion of calcium salts; for the fluoroquinolones an
interval of 4 h is preferable.
As the gastric emptying speed decreases with age and
emptying takes longer in certain patients with specific
conditions (for example in diabetes patients with gastro-
paresisduetoautonomicneuropathy),itisprobablybetter
for all these medicines to maintain aperiod of 4 h between
intake of these medicines and ingestion of calcium salts
(longer if indicated, as in the case of gastroparesis).
Calcium could cause constipation, which can form a
reason to add a laxative, for example, a magnesium salt or
oxide.
Patient preference
Assuming that therapy compliance is an important
subject in the treatment of osteoporosis, any preference
by the patient for a certain medication is probably
also important. There are very few direct comparative
studies on patient preference, also for calcium tablets.
Which form of administration of calcium supplementa-
tion (tablet or effervescent tablet in solution) does the
patient prefer? Do patient-friendly packages combin-
ing calcium and vitamin D and bisphosphonate pro-
mote therapy compliance? Research performed in the
Netherlands used a randomized, open, cross-over trial in
102 patients to compare Calci-Chew D3
†
chewable tablets
to CaD
†
sachets (64). It was determined before the start
that patient preference would be the most important
primary measure of outcome: 67% preferred the chewable
tablet, 19% the sachet, and 15% had no preference (64).
The question that arises is how to interpret this: there was
no difference in clinical relevant factors such as tolerance,
compliance, and adverse effects. Also the actual medica-
tion taken was not significantly different: of the 14 days,
the chewable tablet was taken an average of 12.8 days and
the sachet 13.5 days. One point of criticism on this study
is the extent to which these results over a period of
14 days can be extrapolated to the long term, for example
a period of 5 years. The tolerability was similar for the
two formulations. The authors concluded that patient
preference is very important for medication that should
be used chronically but also that the design of studies and
the interpretation of the data are complicated.
Practical advice for calcium and vitamin D
supplementation
Based on guidelines, optimization of total calcium intake
towards a total of 1,0001,200 mg calcium per day is
considered necessary and sufficient in the context of
osteoporosis and fracture prevention strategies with drug
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diet, mainly milk products (milk, yogurt, or cheese) or
calcium-containing tablets. Dietary calcium intake is pre-
ferred and 34 portions of milk products per day should
be advised. If this cannot be achieved, supplementation of
calcium should be considered. If a patient consumes 12
portions of milk products per day, then the advice is to
add 12 portions of milk products per day or 500 mg of
calcium supplementation. If a patient does not take any
milk products, supplementation of 1,000 mg calcium is
needed. No adjustment is required if the patient consumes
34 portions of milk products per day. In the context of
the concern about cardiovascular conditions, calcium
supplementation should be individualized.
When considering the choice of calcium supplements
one should take into account that fractional calcium
absorption is 24% higher for calcium citrate compared to
calcium carbonate, probably because of higher dissolu-
tion in the ileum, where 65% of the total calcium is
absorbed.Theeffectofprotonpumpinhibitorsoncalcium
absorption are inconclusive as is the case with the effect
of age-related changes in gastric physiology (65). The
practical advice concerning vitamin D supplementation as
part of osteoporosis treatment is to prescribe a minimum
dose of 800 IU per day of vitamin D3. This also applies
to people in nursing homes and care homes and patients
with a recent fracture, irrespective of BMD. Higher
dosages could be considered in case of severe vitamin D
deficiency with secondary hyperparathyroidism.
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